$ATYR
aTyr Pharma Inc

2022 Q4 Form 10-Q Financial Statement

#000095017022024724 Filed on November 14, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $10.39M $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.426M $3.625M $2.590M
YoY Change 27.6% 39.96% 26.96%
% of Gross Profit
Research & Development $14.91M $9.867M $5.138M
YoY Change 150.38% 92.04% 11.31%
% of Gross Profit
Depreciation & Amortization $39.00K $49.00K $123.0K
YoY Change -63.89% -60.16% -5.38%
% of Gross Profit
Operating Expenses $18.34M $13.49M $7.728M
YoY Change 112.22% 74.59% 16.04%
Operating Profit -$13.49M -$7.728M
YoY Change 74.59% 18.67%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $427.0K $247.0K $59.00K
YoY Change 440.51% 318.64% -167.05%
Pretax Income -$7.523M -$13.25M -$7.669M
YoY Change -12.12% 72.71% 16.2%
Income Tax
% Of Pretax Income
Net Earnings -$7.521M -$13.20M -$7.669M
YoY Change -12.13% 72.12% 16.21%
Net Earnings / Revenue -72.41%
Basic Earnings Per Share -$0.46 -$0.42
Diluted Earnings Per Share -$0.26 -$0.46 -$422.2K
COMMON SHARES
Basic Shares Outstanding 29.01M 28.63M 18.16M
Diluted Shares Outstanding 28.66M 18.16M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $66.15M $77.37M $116.4M
YoY Change -38.7% -33.5% 222.31%
Cash & Equivalents $9.981M $18.36M $59.74M
Short-Term Investments $56.17M $59.02M $56.61M
Other Short-Term Assets $2.950M $6.386M $5.089M
YoY Change -43.52% 25.49% 182.72%
Inventory
Prepaid Expenses $2.950M $6.386M
Receivables
Other Receivables $11.78M $873.0K
Total Short-Term Assets $80.87M $84.63M $121.6M
YoY Change -28.79% -30.38% 218.25%
LONG-TERM ASSETS
Property, Plant & Equipment $3.059M $1.275M $2.186M
YoY Change 463.35% -41.67% -33.76%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $193.0K $169.0K $158.0K
YoY Change 22.15% 6.96% 58.0%
Total Long-Term Assets $14.92M $11.42M $2.344M
YoY Change 657.88% 387.29% -31.06%
TOTAL ASSETS
Total Short-Term Assets $80.87M $84.63M $121.6M
Total Long-Term Assets $14.92M $11.42M $2.344M
Total Assets $95.79M $96.06M $123.9M
YoY Change -17.09% -22.48% 197.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.106M $3.129M $900.0K
YoY Change 201.26% 247.67% -35.71%
Accrued Expenses $9.862M $7.269M $4.920M
YoY Change 146.43% 47.74% 36.67%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $264.0K $158.0K
YoY Change
Total Short-Term Liabilities $13.86M $11.21M $5.820M
YoY Change 130.53% 92.66% -27.25%
LONG-TERM LIABILITIES
Long-Term Debt $1.007M $618.0K $0.00
YoY Change
Other Long-Term Liabilities $9.633M $7.218M $657.0K
YoY Change 2320.35% 998.63% -58.94%
Total Long-Term Liabilities $10.64M $7.836M $657.0K
YoY Change 2573.37% 1092.69% -58.94%
TOTAL LIABILITIES
Total Short-Term Liabilities $13.86M $11.21M $5.820M
Total Long-Term Liabilities $10.64M $7.836M $657.0K
Total Liabilities $24.32M $18.87M $6.304M
YoY Change 290.03% 199.35% -33.64%
SHAREHOLDERS EQUITY
Retained Earnings -$417.6M -$410.1M -$363.7M
YoY Change 12.17% 12.76%
Common Stock $29.00K $29.00K
YoY Change 3.57%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $71.46M $77.18M $117.6M
YoY Change
Total Liabilities & Shareholders Equity $95.79M $96.06M $123.9M
YoY Change -17.09% -22.48% 197.88%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$7.521M -$13.20M -$7.669M
YoY Change -12.13% 72.12% 16.21%
Depreciation, Depletion And Amortization $39.00K $49.00K $123.0K
YoY Change -63.89% -60.16% -5.38%
Cash From Operating Activities -$10.37M -$12.28M -$11.47M
YoY Change 28.23% 7.07% 106.67%
INVESTING ACTIVITIES
Capital Expenditures $1.119M -$426.0K -$61.00K
YoY Change -6316.67% 598.36% 510.0%
Acquisitions
YoY Change
Other Investing Activities $3.118M $21.08M -$14.79M
YoY Change -106.32% -242.51% -945.03%
Cash From Investing Activities $1.999M $20.65M -$14.85M
YoY Change -104.05% -239.06% -953.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 918.0K 3.013M 83.87M
YoY Change 3178.57% -96.41% 25314.85%
NET CHANGE
Cash From Operating Activities -10.37M -12.28M -11.47M
Cash From Investing Activities 1.999M 20.65M -14.85M
Cash From Financing Activities 918.0K 3.013M 83.87M
Net Change In Cash -7.452M 11.38M 57.55M
YoY Change -87.02% -80.22% -1753.74%
FREE CASH FLOW
Cash From Operating Activities -$10.37M -$12.28M -$11.47M
Capital Expenditures $1.119M -$426.0K -$61.00K
Free Cash Flow -$11.49M -$11.85M -$11.41M
YoY Change 42.39% 3.91% 105.94%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Type
DocumentType
10-Q
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001339970
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Amendment Flag
AmendmentFlag
false
CY2018Q3 life Lease Extended Maturity Term
LeaseExtendedMaturityTerm
2023-05
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37378
dei Entity Registrant Name
EntityRegistrantName
ATYR PHARMA, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-3435077
dei Entity Address Address Line1
EntityAddressAddressLine1
3545 John Hopkins Court
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite #250
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
731-8389
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
LIFE
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
29009382
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18359000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2336000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
59015000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
105575000
CY2022Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
873000
CY2021Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
435000
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
6386000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
5223000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
84633000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
113569000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2239000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1275000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
543000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6971000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1267000
CY2022Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
768000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
169000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
158000
CY2022Q3 us-gaap Assets
Assets
96055000
CY2021Q4 us-gaap Assets
Assets
115537000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3129000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1031000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7269000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4002000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
657000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
980000
CY2022Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
158000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
11213000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6013000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7218000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
398000
CY2022Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
618000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
85000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
42500000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29009382
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29009382
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27793035
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27793035
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
29000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
28000
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
487937000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
481832000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-669000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-263000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-410113000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-372296000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
77184000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
109301000
CY2022Q3 us-gaap Minority Interest
MinorityInterest
-178000
CY2021Q4 us-gaap Minority Interest
MinorityInterest
-175000
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
77006000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
109126000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
96055000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
115537000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9867000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5138000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27898000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17309000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3625000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2590000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10556000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8066000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
13492000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
7728000
us-gaap Operating Expenses
OperatingExpenses
38454000
us-gaap Operating Expenses
OperatingExpenses
25375000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13492000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7728000
us-gaap Operating Income Loss
OperatingIncomeLoss
-38454000
us-gaap Operating Income Loss
OperatingIncomeLoss
-25375000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
247000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
59000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
634000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
159000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-13245000
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-7669000
us-gaap Profit Loss
ProfitLoss
-37820000
us-gaap Profit Loss
ProfitLoss
-25216000
CY2022Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1000
CY2021Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-2000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-3000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-7000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-13244000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-7667000
us-gaap Net Income Loss
NetIncomeLoss
-37817000
us-gaap Net Income Loss
NetIncomeLoss
-25209000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.46
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.46
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.42
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.42
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.34
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.34
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.56
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.56
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28663047
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28663047
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18159231
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18159231
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28184698
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28184698
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16145351
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16145351
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-13245000
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-7669000
us-gaap Profit Loss
ProfitLoss
-37820000
us-gaap Profit Loss
ProfitLoss
-25216000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
141000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-8000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-406000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-26000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-13104000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-7677000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-38226000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-25242000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-1000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-2000
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-3000
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-7000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13103000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7675000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-38223000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25235000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
109126000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2022Q1 life Stock Issued During Period Value At The Market Offerings Net Of Offering Costs
StockIssuedDuringPeriodValueAtTheMarketOfferingsNetOfOfferingCosts
1480000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
417000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-496000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-12154000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
98374000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
5000
CY2022Q2 life Stock Issued During Period Value At The Market Offerings Net Of Offering Costs
StockIssuedDuringPeriodValueAtTheMarketOfferingsNetOfOfferingCosts
34000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
517000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-51000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-12421000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
86458000
CY2022Q3 life Stock Issued During Period Value At The Market Offerings Net Of Offering Costs
StockIssuedDuringPeriodValueAtTheMarketOfferingsNetOfOfferingCosts
3037000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
615000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
141000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-13245000
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
77006000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
31484000
CY2021Q1 life Stock Issued During Period Value At The Market Offerings Net Of Offering Costs
StockIssuedDuringPeriodValueAtTheMarketOfferingsNetOfOfferingCosts
9621000
CY2021Q1 life Issuance Of Common Stock From Committed Purchase Agreement Net Of Offering Costs
IssuanceOfCommonStockFromCommittedPurchaseAgreementNetOfOfferingCosts
15236000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
360000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-14000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-7155000
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
49532000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
5000
CY2021Q2 life Stock Issued During Period Value At The Market Offerings Net Of Offering Costs
StockIssuedDuringPeriodValueAtTheMarketOfferingsNetOfOfferingCosts
1265000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
398000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-4000
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-10392000
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
40805000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
58000
CY2021Q3 life Stock Issued During Period Value At The Market Offerings Net Of Offering Costs
StockIssuedDuringPeriodValueAtTheMarketOfferingsNetOfOfferingCosts
3184000
CY2021Q3 life Issuance Of Common Stock From Underwritten Follow On Offering Net Of Offering Costs
IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCosts
80627000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
442000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-8000
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-7669000
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
117439000
us-gaap Profit Loss
ProfitLoss
-37820000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
617000
us-gaap Profit Loss
ProfitLoss
-25216000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
193000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
367000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1549000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1200000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-565000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-143000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
805000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
95000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-70000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-1910000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1174000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3244000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
4878000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-133000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-488000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-633000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31517000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24989000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
522000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
174000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
17124000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
68811000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
62713000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
26767000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
179000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
45246000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-42218000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
59000
life Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
5000
life Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
5000
life Proceeds From Issuance Of Common Stock Through At Market Offering Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockThroughAtMarketOfferingNetOfOfferingCosts
4551000
life Proceeds From Issuance Of Common Stock Through At Market Offering Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockThroughAtMarketOfferingNetOfOfferingCosts
14070000
life Proceeds From Issuance Of Common Stock Through Committed Purchase Agreement Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockThroughCommittedPurchaseAgreementNetOfOfferingCosts
15236000
life Proceeds From Issuance Of Common Stock Through Underwritten Follow On Offering Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockThroughUnderwrittenFollowOnOfferingNetOfOfferingCosts
80627000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
24000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4533000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
109997000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
18262000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
42790000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2336000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
16952000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
20598000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
59742000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18359000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
59742000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2239000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
20598000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
59742000
life Purchases Of Property And Equipment In Accounts Payable
PurchasesOfPropertyAndEquipmentInAccountsPayable
487000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
800000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-13200000
us-gaap Net Income Loss
NetIncomeLoss
-37800000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-410100000
CY2022Q3 life Cash And Cash Equivalents Restricted Cash And Available For Sale Investments
CashAndCashEquivalentsRestrictedCashAndAvailableForSaleInvestments
79600000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2200000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:5.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our unaudited condensed consolidated financial statements are prepared in accordance with U.S. GAAP. The preparation of our unaudited condensed consolidated financial statements requires us to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure for these items in our unaudited condensed consolidated financial statements and accompanying notes. The most significant estimates in our unaudited condensed consolidated financial statements relate to clinical trial and research and development expenses. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ materially from these estimates and assumptions.</span></p>
CY2021Q1 life Milestone Payment Received
MilestonePaymentReceived
2000000.0
CY2021Q1 life Milestone Payment Received
MilestonePaymentReceived
2000000.0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3114890
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1294576
CY2022Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
59634000
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
619000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
59015000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
105788000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
213000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
105575000
CY2022Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
7
CY2022Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
26
CY2022Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
13400000
CY2020Q1 life Upfront Payment Received
UpfrontPaymentReceived
8000000.0
CY2021Q1 life Milestone Payment Received
MilestonePaymentReceived
2000000.0
CY2020Q1 life Upfront Payment Received
UpfrontPaymentReceived
8000000.0
CY2018Q3 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
false
CY2022Q2 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
23696
CY2022Q2 us-gaap Lessee Operating Lease Lease Not Yet Commenced Term Of Contract1
LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1
P124M
us-gaap Lessee Operating Lease Lease Not Yet Commenced Option To Extend
LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend
We also have one option to extend the Lease Term for five years.
CY2022Q2 us-gaap Lessee Operating Lease Lease Not Yet Commenced Existence Of Option To Extend
LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend
true
CY2022Q2 us-gaap Lessee Operating Lease Lease Not Yet Commenced Renewal Term1
LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1
P5Y
CY2022Q2 life Base Rent Per Square Foot
BaseRentPerSquareFoot
5.75
CY2022Q2 life Annual Upward Adjustments On Base Rate Percentage
AnnualUpwardAdjustmentsOnBaseRatePercentage
0.030
CY2022Q2 us-gaap Tenant Improvements
TenantImprovements
5500000
CY2022Q2 life Additional Allowance For Tenant Improvements
AdditionalAllowanceForTenantImprovements
600000
CY2022Q2 life Base Rent Amortized Percentage
BaseRentAmortizedPercentage
-0.080
CY2022Q3 us-gaap Security Deposit
SecurityDeposit
700000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
270000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1085000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1675000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1726000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1777000
CY2022Q3 life Lessee Operating Lease Liability Payments Due Year Six And There After
LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereAfter
12933000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
7019000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
12447000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
657000
CY2022Q3 life Lessee Operating Lease Liability Tenant Improvement Allowance Not Yet Received
LesseeOperatingLeaseLiabilityTenantImprovementAllowanceNotYetReceived
4572000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7218000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
300000
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
200000
us-gaap Operating Lease Cost
OperatingLeaseCost
800000
us-gaap Operating Lease Cost
OperatingLeaseCost
700000
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P10Y4M24D
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.088
CY2022Q3 us-gaap Lessee Finance Lease Term Of Contract1
LesseeFinanceLeaseTermOfContract1
P48M
CY2022Q3 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
52000
CY2022Q3 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
208000
CY2022Q3 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
208000
CY2022Q3 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
208000
CY2022Q3 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
223000
CY2022Q3 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
123000
CY2022Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
776000
CY2022Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
158000
CY2022Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
618000
CY2022Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P3Y9M18D
CY2022Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.072
CY2021Q1 life Commission Rate Equal To Gross Proceeds1
CommissionRateEqualToGrossProceeds1
0.030
CY2022Q2 life Commission Rate Equal To Gross Proceeds1
CommissionRateEqualToGrossProceeds1
0.030
CY2022Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4971922
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1412550
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.01
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1573844
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.44
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
259
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.77
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
25505
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
12.27
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2960630
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.45
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
615000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
442000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1549000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1200000

Files In Submission

Name View Source Status
0000950170-22-024724-index-headers.html Edgar Link pending
0000950170-22-024724-index.html Edgar Link pending
0000950170-22-024724.txt Edgar Link pending
0000950170-22-024724-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
life-20220930.htm Edgar Link pending
life-20220930.xsd Edgar Link pending
life-ex31_1.htm Edgar Link pending
life-ex31_2.htm Edgar Link pending
life-ex32_1.htm Edgar Link pending
life-ex32_2.htm Edgar Link pending
life-ex3_1.htm Edgar Link pending
life-ex3_6.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
life-20220930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
life-20220930_lab.xml Edgar Link unprocessable
life-20220930_htm.xml Edgar Link completed
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
life-20220930_def.xml Edgar Link unprocessable
life-20220930_cal.xml Edgar Link unprocessable